Email
Mot de passe
Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Ou connectez-vous avec votre réseau social favori

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

Double Bond Pharmaceutical

Double Bond Pharmaceutical_logo
4
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Uppsala, Uppsala, Sweden

Send a message

Anglais

Double Bond Pharmaceutical Who are we?

Double Bond Pharmaceutical (DBP) is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company's both front-line products were recently granted Orphan Drug Designation status by European Medicines Agency (EMA): in June 2015 for its first product, SA-033, for treatment of hepatoblastoma (liver cancer), and in July 2016 for its second product, Temodex, for treatment of brain...

See more

Double Bond Pharmaceutical (DBP) is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company's both front-line products were recently granted Orphan Drug Designation status by European Medicines Agency (EMA): in June 2015 for its first product, SA-033, for treatment of hepatoblastoma (liver cancer), and in July 2016 for its second product, Temodex, for treatment of brain tumours. DBP has acquired Temodex from Belarus in October 2015 and the drug is already registered and used as a first-line treatment of glioblastoma in Belarus since 2014.

Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not received funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
481 Entities

Communities